Historical Stock Price
ETFs Holding ACAD »    Stock Splits Calendar »
Video: Compound Annual Growth Rate (CAGR) Definition


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Date Open High Low Close Volume
04/24/2017 $32.66 $33.83 $32.41 $33.72 1.44M
04/25/2017 $33.98 $36.20 $33.93 $34.71 2.40M
04/26/2017 $34.77 $35.22 $33.61 $33.66 1.39M
04/27/2017 $33.68 $33.92 $33.08 $33.83 1.04M
04/28/2017 $33.87 $34.39 $33.50 $34.33 1.07M
Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system (CNS), disorders. Co. has a portfolio of product led by its novel drug, NUPLAZID® (pimavanserin), for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD) Psychosis. Co. owns or has rights to various trademarks, copyrights and trade names used in its business, including ACADIA® and NUPLAZID®.
ACAD historical stock prices picture
Acadia Pharmaceuticals (ACAD) has the following price history information. Looking back at ACAD historical stock prices for the last five trading days, on April 24, 2017, ACAD opened at $32.66, traded as high as $33.83 and as low as $32.41, and closed at $33.72. Trading volume was a total of 1.44M shares. On April 25, 2017, ACAD opened at $33.98, traded as high as $36.20 and as low as $33.93, and closed at $34.71. Trading volume was a total of 2.40M shares. On April 26, 2017, ACAD opened at $34.77, traded as high as $35.22 and as low as $33.61, and closed at $33.66. Trading volume was a total of 1.39M shares. On April 27, 2017, ACAD opened at $33.68, traded as high as $33.92 and as low as $33.08, and closed at $33.83. Trading volume was a total of 1.04M shares. On April 28, 2017, ACAD opened at $33.87, traded as high as $34.39 and as low as $33.50, and closed at $34.33. Trading volume was a total of 1.07M shares.

ACAD Historical Stock Prices By Date:

ACAD historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acadia Pharmaceuticals shares, starting with a $10,000 purchase of ACAD, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/01/2007
End date: 04/28/2017
Start price/share: $13.50
End price/share: $34.33
Dividends collected/share: $0.00
Total return: 154.30%
Average Annual Total Return: 9.78%
Starting investment: $10,000.00
Ending investment: $25,423.32
Years: 10.00
Date Close
04/24/2017$33.72
04/25/2017$34.71
04/26/2017$33.66
04/27/2017$33.83
04/28/2017$34.33
ACAD is categorized under the Healthcare sector; below are some other companies in the same sector:

ACET Historical Stock Prices
ACHC Historical Stock Prices
ACHN Historical Stock Prices
ACIU Historical Stock Prices
ACOR Historical Stock Prices
ACRS Historical Stock Prices
ACRX Historical Stock Prices
ACST Historical Stock Prices
ACUR Historical Stock Prices
ADAP Historical Stock Prices

ACAD Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.